Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 29293895.
- Also identified by DOI 10.1093/cid/cix1131 and PMC identifier 5961309.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
NCT02263326.
Medical subject headings
- Anti-HIV Agents
- HIV Infections
- HIV-1
- Heterocyclic Compounds, 3-Ring
- Lamivudine